Exploring human CYP4 enzymes: Physiological roles, function in diseases and focus on inhibitors. Issue 5 (May 2023)

• Record Type: Journal Article
• Authors: Zhou, Manzhen; Li, Junda; Xu, Jinyi; Zheng, Lufeng; Xu, Shengtao
• Is Part Of: Drug discovery today. Volume 28:Issue 5(2023)
• Publication Date: 2023-05
• Subjects: CYP450 -- CYP4 -- ω-hydroxylation -- CYP4 inhibitors -- endogenous fatty acid; Drugs -- Design -- Periodicals; Drugs -- Research -- Periodicals; 615.1
• DOI: 10.1016/j.drudis.2023.103560
• Languages: English
• ISSNs: 1359-6446

Abstract

Graphical abstract: Highlights: The cytochrome P450 4 (CYP4) family of enzymes is responsible for the activation or deactivation of numerous endogenous substrates. CYP4 is a vital therapeutic target for related human diseases, including cancer, cardiovascular diseases and inflammation. CYP4 enzymes inhibitors are divided into three main categories by structure. This review provides clues for the future discovery of drug candidates targeting CYP4. Abstract : The cytochrome P450 (CYP)4 family of enzymes are monooxygenases responsible for the ω-oxidation of endogenous fatty acids and eicosanoids and play a crucial part in regulating numerous eicosanoid signaling pathways. Recently, CYP4 gained attention as a potential therapeutic target for several human diseases, including cancer, cardiovascular diseases and inflammation. Small-molecule inhibitors of CYP4 could provide promising treatments for these diseases. The aim of the present review is to highlight the advances in the field of CYP4, discussing the physiology and pathology of the CYP4 family and compiling CYP4 inhibitors into groups based on their chemical classes to provide clues for the future discovery of drug candidates targeting CYP4.